TapImmune: tapping into innovative cancer treatments

In just five years Glynn Wilson, chief executive of TapImmune, estimates the Seattle-based company will be worth more than a $1 billion. It’s a big claim to make for a company that currently is not making money but Wilson sees no reason why it can’t aim for the top.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

WBD to merge with firm to create ‘powerhouse’ practice

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

AstraZeneca unit draws line under Samsung dispute

TapImmune: tapping into innovative cancer treatments

Editor's picks

Editor's picks

More features